Loading
Radiation turns the irradiated tumour into a vaccine; immunotherapy spreads the response.
This combination pairs SBRT / SABR (stereotactic radiotherapy) and other radiotherapy with Immune checkpoint inhibitors: radiation turns the irradiated tumour into a vaccine and immunotherapy spreads the response. Radiation induces immunogenic cell death, cGAS-STING innate sensing, MHC upregulation and antigen release, and PD-L1 rises afterwards, which checkpoint blockade counters. Phase 3 trials are positive in consolidation settings, notably PACIFIC (Durvalumab after chemoradiation in Non-small-cell lung cancer, with overall survival benefit), KEYNOTE-A18 in Cervical cancer and NRG/RTOG trials. The Abscopal effect with SBRT plus immunotherapy is real but inconsistent, with PEMBRO-RT positive and other trials negative, so timing, dose and site matter.
Shares An oncology patent pool for combination trials across companies, cGAS-STING innate sensing, Pembrolizumab, Immune checkpoint inhibitors.
Shares Abscopal effect, SBRT / SABR (stereotactic radiotherapy), Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Abscopal effect, SBRT / SABR (stereotactic radiotherapy), Immune checkpoint inhibitors.
Shares Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Durvalumab, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares An oncology patent pool for combination trials across companies, A neutral platform trial for radiotherapy plus immunotherapy combinations.